<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03858387</url>
  </required_header>
  <id_info>
    <org_study_id>B-lactams-ICU-61061141</org_study_id>
    <nct_id>NCT03858387</nct_id>
  </id_info>
  <brief_title>PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients</brief_title>
  <official_title>Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Î²-lactams in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meropenem and imipenem are broad-spectrum carbapenem antibiotic and are frequently prescribed
      in critically ill patients with severe infections. These patients show several
      pathophysiological changes that may alter the carbapenem pharmacokinetic (PK) normally found
      in other populations. Although the PK of carbapenems has been widely studied, most studies
      have been conducted on small populations, and clinical outcome data are sparse. Therefore,
      the aims of this study are (i) describe the population pharmacokinetic parameters of
      meropenem and imipenem in critically ill subject (ii) evaluate the pharmacodynamic of
      meropenem and imipenem as a predictor of clinical treatment outcome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Population pharmacokinetic parameters of meropenem and imipenem</measure>
    <time_frame>24-48 hours after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>%fT&gt;MIC of meropenem and imipenem</measure>
    <time_frame>24-48 hours after treatment</time_frame>
    <description>the percentage of time which the free drug concentration remains above the minimum inbibitory concentration (%fT&gt;MIC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The relationship between %fT&gt;MIC and clinical cure</measure>
    <time_frame>Day 3-7 after treatment and end of therapy (7-14)</time_frame>
    <description>Clinical cure: disappearance of all signs and symptoms related to the infection, such that no additional antibacterial therapy, drainage, or surgical procedure was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between %fT&gt;MIC and microbiological cure</measure>
    <time_frame>Day 3-7 after treatment and end of therapy (7-14)</time_frame>
    <description>Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between %fT&gt;MIC and mortality</measure>
    <time_frame>during hospital stay and at day 28</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Critical Illness</condition>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <description>Critically ill patients who require meropenem therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipenem</arm_group_label>
    <description>Critically ill patients who require imipenem therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case.
Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration.</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem</intervention_name>
    <description>This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case.
Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration.</description>
    <arm_group_label>Imipenem</arm_group_label>
    <other_name>Imipenem/cilastatin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years

          -  severely ill patient who admitted to medical or surgical intensive care unit who
             require a treatment with meropenem or imipenem antibiotic

        Exclusion Criteria:

          -  severe renal impairment and require renal replacement therapy

          -  APACHE II score &gt;30

          -  History of hypersensitivity to carbapenems

          -  Pregnancy or breast-feeding female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sutep Jaruratanasirikul, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Prince of Songkla University, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sutep o Jaruratanasirikul, M.D.</last_name>
    <phone>6674451485</phone>
    <phone_ext>6674451485</phone_ext>
    <email>jasutep@medicine.psu.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monchana o Nawakitrangsan, M.Pharm.</last_name>
    <phone>6674451485</phone>
    <phone_ext>6674451485</phone_ext>
    <email>nana_jittung@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Prince of Songkla University, Thailand</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sutep Jaruratanasirikul, M.D.</last_name>
      <phone>6674-451485</phone>
      <email>jasutep@medicine.psu.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Monchana Nawakitrangsan, M.Pharm</last_name>
      <phone>6674-451486</phone>
      <email>nana_jittung@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sutep Jaruratanasirikul, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 24, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Sutep Jaruratanasirikul</investigator_full_name>
    <investigator_title>Department of Medicine, Faculty of Medicine, Prince of Songkla University</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>meropenem</keyword>
  <keyword>imipenem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

